Treatment of coronary lesions with a novel crystalline sirolimus-coated balloon

• DOI: 10.3389/fcvm.2024.1316580
• Publication Date: 2024-02-13T04:30:24Z
• Authors: Mehdi Madanchi; Adrian Attinger-T...; Varis Gjergjizi; Irena Majcen; Giacomo M. Cioffi; Angelika Epper; Eleonora Gnan; Tanja Koch; Yuan Zhi; Florim Cuculi; Matthias Bossard
• Keywords: paclitaxel; sirolimus; 0302 clinical medicine; RC666-701; complex coronary lesions; percutaneous coronary intervention; Diseases of the circulatory (Cardiovascular) system; Cardiovascular Medicine; drug-coated balloons; drug eluting stent

BackgroundThere is mounting data supporting the use of drug-coated balloons (DCB) not only for treatment of in-stent restenosis (ISR), but also in native coronary artery disease. So far, paclitaxel-coated balloons represented the mainstay DCBs. The SeQuent® crystalline sirolimus-coated balloon (SCB) (B.Braun Medical Inc, Germany) represents a novel DCB, which allows a sustained release of the limus-drug. We evaluated its performance in an all-comer cohort, including complex coronary lesions.MethodsConsecutive patients treated with the SeQuent® SCB were analyzed from the prospective SIROOP registry (NCT04988685). We assessed clinical outcomes, including major adverse cardiovascular events (MACE), target lesion revascularization (TLR), target vessel myocardial infarction (TV-MI) and cardiovascular death. Angiograms and outcomes were independently adjudicated.ResultsFrom March 2021 to March 2023, we enrolled 126 patients and lesions, of which 100 (79%) treated using a “DCB-only” strategy and 26 (21%) with a hybrid approach (DES + DCB). The mean age was 68 ± 10 years, 48 (38%) patients had an acute coronary syndrome. Regarding lesion characteristics, ISR was treated in 27 (21%), 11 (9%) underwent CTO-PCI and 59 (47%) of the vessels were moderate to severe calcified. Procedural success rate was 100%. At a median follow-up time of 12.7 (IQR 12; 14.2) months, MACE occurred in 5 patients (4.3%). No acute vessel closure was observed.ConclusionsOur data indicates promising outcomes following treatment with this novel crystalline SCB in an all-comer cohort with complex coronary lesions. These results require further investigation with randomized trials.